OptimizeRx Recognized as One of The Americas’ Fastest-Growing Companies by The Financial Times
2020年4月9日 - 1:30AM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies and payers, has
received the ranking of #282 by the Financial Times’ 2020 list of
The Americas' 500 Fastest-Growing Companies.
The FT Americas list was compiled in coordination with the
leading research firm Statista, which ranked the top 500 companies
in North and South America by their compounded annual revenue
growth rate between 2015 and 2018. OptimizeRx’s growth rate
exceeded 43% during the period.
"We’re honored to be recognized by the Financial Times, one of
the world's most widely read and respected business publications,"
said William Febbo, CEO of OptimizeRx. “Our strong ranking reflects
the tremendous efforts and dedication of our team which has driven
this strong growth and market expansion. We are in the right place
at the right time with technology solutions for physicians,
patients and clients. We expect our integrated digital heath
platform to accelerate our business and grow our recurring revenue
over the coming years.
“Our platform allows us to expand within our existing client
base with a suite of solutions that are critical to not only a
successful product launch but the support it needs over its life in
the market. Given our digital health network now reaches more than
300,000 healthcare providers across the U.S., we expect our team to
drive another year of record growth in 2020.”
About the Financial Times The Financial Times
(FT) is one of the world’s leading business news organizations,
recognized internationally for its authority, integrity and
accuracy. The FT has a paying readership of more than a million
worldwide, three-quarters of which are digital subscriptions. FT is
part of Nikkei Inc., which provides a broad range of information,
news and services for the global business community. For more
information, visit www.ft.com.
About OptimizeRxOptimizeRx® (NASDAQ: OPRX), a
digital health company, connects pharmaceutical companies to
patients and providers, offering greater affordability, adherence
and brand awareness at the point-of-care. As the nation’s largest
digital platform connecting life sciences to the point-of-care,
OptimizeRx provides a direct channel for pharma companies, payers,
medtech, and medical associations to communicate with healthcare
providers right within their workflow and also directly to
patients.
The cloud-based solution supports patient adherence to
medications and better healthcare outcomes with real-time access to
financial assistance, prior authorization, education and critical
clinical information. OptimizeRx provides more than half of the
ambulatory patient market with access to these benefits through
leading EHR platforms like Allscripts, Amazing Charts and Quest,
and directly via its mobile communications platform and digital
therapeutics SaaS platform.
For more information, follow the company on Twitter, LinkedIn or
visit www.OptimizeRx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, and other material
risks.
OptimizeRx Contact Doug Baker, CFOTel (248)
651-6568 x807 dbaker@optimizerx.com
Media Relations Contact Maira Alejandra, Media
Relations ManagerTel (754) 245-7070 malejandra@optimizerx.com
Investor Relations Contact Ron Both, CMATel
(949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 6 2024 まで 7 2024
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 7 2023 まで 7 2024